GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » PolyPeptide Group AG (XSWX:PPGN) » Definitions » Enterprise Value

PolyPeptide Group AG (XSWX:PPGN) Enterprise Value : CHF1,092.2 Mil (As of Jun. 06, 2024)


View and export this data going back to 2021. Start your Free Trial

What is PolyPeptide Group AG Enterprise Value?

Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, PolyPeptide Group AG's Enterprise Value is CHF1,092.2 Mil. PolyPeptide Group AG's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was CHF-50.7 Mil. Therefore, PolyPeptide Group AG's EV-to-EBIT ratio for today is -21.52.

EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, PolyPeptide Group AG's Enterprise Value is CHF1,092.2 Mil. PolyPeptide Group AG's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was CHF-21.5 Mil. Therefore, PolyPeptide Group AG's EV-to-EBITDA ratio for today is -50.76.

EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, PolyPeptide Group AG's Enterprise Value is CHF1,092.2 Mil. PolyPeptide Group AG's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was CHF306.4 Mil. Therefore, PolyPeptide Group AG's EV-to-Revenue ratio for today is 3.56.


PolyPeptide Group AG Enterprise Value Historical Data

The historical data trend for PolyPeptide Group AG's Enterprise Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PolyPeptide Group AG Enterprise Value Chart

PolyPeptide Group AG Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Enterprise Value
Get a 7-Day Free Trial - - 4,412.22 817.59 594.56

PolyPeptide Group AG Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Enterprise Value Get a 7-Day Free Trial Premium Member Only Premium Member Only 4,412.22 2,099.79 817.59 685.68 594.56

Competitive Comparison of PolyPeptide Group AG's Enterprise Value

For the Drug Manufacturers - Specialty & Generic subindustry, PolyPeptide Group AG's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PolyPeptide Group AG's Enterprise Value Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, PolyPeptide Group AG's Enterprise Value distribution charts can be found below:

* The bar in red indicates where PolyPeptide Group AG's Enterprise Value falls into.



PolyPeptide Group AG Enterprise Value Calculation

Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

PolyPeptide Group AG's Enterprise Value for the fiscal year that ended in Dec. 2023 is calculated as

PolyPeptide Group AG's Enterprise Value for the quarter that ended in Dec. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


PolyPeptide Group AG  (XSWX:PPGN) Enterprise Value Explanation

When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.

If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.

The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.

For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.

Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.

1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.

PolyPeptide Group AG's EV-to-EBIT for today is

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=1092.198/-50.742
=-21.52

PolyPeptide Group AG's current Enterprise Value is CHF1,092.2 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. PolyPeptide Group AG's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was CHF-50.7 Mil.

2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.

PolyPeptide Group AG's EV-to-EBITDA for today is:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA(TTM)
=1092.198/-21.518
=-50.76

PolyPeptide Group AG's current Enterprise Value is CHF1,092.2 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. PolyPeptide Group AG's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was CHF-21.5 Mil.

3. EV-to-Revenue is calculated as Enterprise Value divided by its Revenue.

PolyPeptide Group AG's EV-to-Revenue for today is:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=1092.198/306.412
=3.56

PolyPeptide Group AG's current Enterprise Value is CHF1,092.2 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. PolyPeptide Group AG's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was CHF306.4 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


PolyPeptide Group AG Enterprise Value Related Terms

Thank you for viewing the detailed overview of PolyPeptide Group AG's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.


PolyPeptide Group AG (XSWX:PPGN) Business Description

Traded in Other Exchanges
Address
Neuhofstrasse 24, Baar, Zug, CHE, 6340
PolyPeptide Group AG is an independent contract development and manufacturing organization (CDMO) focused on peptides and oligonucleotides employed as an active pharmaceutical ingredients (APIs) and used as intermediates in therapeutic products. The company derives a majority of its revenue from Europe and Asia.

PolyPeptide Group AG (XSWX:PPGN) Headlines

No Headlines